Thursday, December 28, 2023

NOVEL BI-LAYERED EXPANDED POLYTETRAFLUOROETHYLENE GLAUCOMA IMPLANT

 


A promising and incompletely explored approach to fibrosis control utilizes biomaterials that modulate healing. Expanded polytetrafluoroethylene (ePTFE) is a highly stable polymer of tetrafluoroethylene that was patented by Gore. 

Due to its biocompatibility, biostability, and high compliance, ePTFE incorporates well into many tissues and is approved for use in numerous biomedical implants, including: vascular grafts, bypass grafts, hernia membranes, and sutures. ePTFE has a porous surface comprised of nodes and fibrils which can structurally permit or prevent cellular integration. 

Implants of matching footprints were fabricated from silicone (Control) and novel, bi-layered ePTFE.

ePTFE implants included: (a) one that inflated with aqueous humor (AH) (High), (b) one that inflated with a lower profile (Low), (c) an uninflated implant not connected to the anterior chamber (Flat), and (d) one filled with material that did not allow AH flow (Filled).





All implants were placed in adult New Zealand White rabbits and followed over 1–3 months.

  • The permeability of tissue capsules surrounding GDIs was assessed using constant-flow perfusion with fluoresceinated saline at physiologic flow rates.
  • After sacrifice, quantitative histopathological measures of capsule thickness were compared among devices, along with qualitative assessment of cellular infiltration and inflammation.
  • Capsular thickness was significantly reduced in blebs over ePTFE (61.4 ±53μm) versus silicone implants (193.6 ±53μm, p =.0086).
  • AH exposure did not significantly alter capsular thickness, as there was no significant difference between High and Filled (50.9 ±29, p =.34) implants.
  • Capsules around ePTFE implants demonstrated permeability with steady-state pressure: flow relationships at physiologic flow rates and rapid pressure decay with flow cessation, while pressure in control blebs increased even at low flow rates and showed little decay.
  • Perfused fluorescein dye appeared beyond the plate border only in ePTFE implants.




Steady fluorescein outflow beyond the ePTFE implant 


In conclusion, ePTFE implants are associated with thinner, more permeable capsules compared to silicone implants simulating presently used devices.

ARTICLE LINK: https://aiche.onlinelibrary.wiley.com/doi/full/10.1002/btm2.10179






Sunday, December 24, 2023

The mechanical theory of glaucoma in terms of prelaminar, laminar, and postlaminar factors

 


The mechanical theory is one of the oldest concepts regarding the development of glaucomatous neural degeneration. However, after a prolonged period of relative monopoly among the various theories explaining the pathogenesis of glaucoma, this concept gradually faded away from discourse. 




Several developments in the recent past have rekindled interest in the mechanical theory of glaucoma. Now we know a lot more about the biomechanics of the eye, prelaminar changes, mechanisms of retinal ganglion cell death, biomechanical features of the optic nerve head and sclera, extracellular matrix composition and its role, astrocytic changes, axoplasmic flow, and postlaminar factors such as translaminar pressure difference. These factors and others can be categorized into prelaminar, laminar, and postlaminar elements. 

The objective of this review was to present a concise analysis of these recent developments. 

The review has been published as a pre-print (Ahead of publication) in the Taiwan Journal of Ophthalmology.





Monday, December 18, 2023

iDose TR Travoprost intracameral implant

 


Glaukos Corporation, the company which developed the iStent device, has announced the FDA approval of their single administration iDose TR travoprost intracameral implant.

The device is made from medical-grade titanium and measures 1.8 mm × 0.5 mm. It is implanted using a technique similar to many MIGS procedures. A gonioprism is used to identify the anterior chamber (AC) angle, a 2.2 mm incision is made in clear cornea, the AC is filled with a cohesive viscoelastic and the device is implanted through the trabecular meshwork and the back of the Schlemm’s canal directly into the scleral tissue. The device is held in place by a scleral anchor. After the end of the specified period, the device is replaced by a new one. According to some, the device can be used for 4-5 years.



The device has a membrane-bound reservoir of 75 mcg travoprost which diffuses continuously into the anterior chamber. There are two iDose TR models available, which have two different rates of drug elution (referred to as fast- and slow-release iDose TR models). This drug-delivery platform circumvents the patient compliance issue which plagues many glaucoma patients.




Contraindications:

iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings and Precautions:

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions:

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Studies:

The FDA approval is based on results from two prospective, randomized, multicenter, double-masked, Phase 3 pivotal trials (GC-010 and GC-012) designed to compare the safety and efficacy of a single administration of one of two iDose TR models with different travoprost release rates (referred to as the fast- and slow-release iDose TR models, respectively) to topical timolol ophthalmic solution, 0.5% BID (twice a day), in reducing IOP in subjects with open-angle glaucoma or ocular hypertension. In total, the Phase 3 trials randomized 1,150 subjects across 89 clinical sites. The FDA approval and Phase 3 data referenced below is for the slow-release iDose TR model, consistent with the company’s NDA submission and commercialization plans.

Both Phase 3 trials successfully achieved the pre-specified primary efficacy endpoints through 3 months and demonstrated a favorable tolerability and safety profile through 12 months. IOP reductions from baseline over the first 3 months were 6.6-8.4 mmHg in the iDose TR arm, versus 6.5-7.7 mmHg in the timolol control arm.

 iDose TR demonstrated non-inferiority to timolol ophthalmic solution in IOP reduction during the first 3 months. The FDA also noted that subsequently iDose TR did not demonstrate non-inferiority over the next 9 months.

At 12 months, 81% of iDose TR subjects were completely free of IOP-lowering topical medications across both trials. In both trials, iDose TR demonstrated excellent tolerability and subject retention with 98% of iDose TR subjects continuing in the trial at 12 months, versus 95% of timolol control subjects. In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of iDose TR patients were increases in intraocular pressure, iritis, dry eye, and visual field defects, most of which were mild and transient in nature.





Thursday, December 14, 2023

OPTICAL COHERENCE ELASTOGRAPHY (OCE)


 


Optical coherence elastography (OCE) is an emerging biomedical imaging technique used to produce images of biological tissue in micron and submicron level and map the biomechanical property of tissues. This technology is based on the currently popular optical coherence tomography (OCT) technique. In theory, OCT generates a structural image based on light scattering determined by minute changes in the refractive index of different tissue and cell types, while OCE utilizes local tissue motion as a function of an applied stress to infer tissue stiffness (i.e., elasticity).




Many diseases affect the structural organization and function of human cells, collagen fibers, and extracellular matrix. Therefore, changes in local elastic moduli may be used to diagnose and help manage treatment of diseased tissue within the cornea, sclera, lens, and retina. Biomechanical testing can be comparatively advantageous to probe structural characteristics in both diseased and healthy tissues that are difficult to contrast using classical OCT methods.

The goal of OCE is to produce images of tissue elastic and viscoelastic properties, and ultimately quantitative maps of the static (i.e., low-frequency) Young’s modulus from maps of tissue displacements and strains detected with OCT.

An OCE system uses three steps to obtain information related to tissue elasticity: (1) mechanical loading, (2) tissue response, and (3) motion detection.



Elasticity imaging requires a physical stress to deform (displace) tissue. Resulting displacements are measured with OCT to compute strains, detect vibrations, or track the propagation of a mechanical wave. The stress–strain response of tissue, local vibration behavior, or mechanical wave content, can each be mapped spatially to solve for metrics such as the Young’s (or shear) modulus.



Mechanical loading methods are static and dynamic using both contact and noncontact approaches. For clinical applications in the anterior segment of the eye, it appears that dynamic, noncontact methods are the most translatable. Current noncontact methods include air-puff excitation, optical excitation, and acoustic microtapping (AμT) using air-coupled ultrasound. For measurements in the cornea (and sclera), optical excitation and AμT provide high bandwidth and spatially precise excitation well-matched to mechanical wave analysis.

Soft tissue responds to dynamic loading by launching mechanical waves. Broadband excitations produce mechanical waves, which in bulk materials exhibit wave speed and attenuation directly related to tissue viscoelastic parameters. Using these methods, robust, quantitative elasticity maps of structures within the anterior segment of the eye, especially the cornea, are possible.

Precise knowledge of corneal biomechanics is critical for early diagnosis, optimal management of diseased corneas (e.g., keratoconus) and predicting the risks of surgical intervention of healthy corneas, such as post-LASIK ectasia. In addition, traditional IOP measurements using direct contact are often con founded by the elastic properties of the cornea. Instruments such as the ORA and DSA attempt to account for these properties by monitoring the corneal response to a dynamic mechanical stimulus as part of IOP measurement. Dynamic tonometry is being considered as a potential screening tool for glaucoma and myopia, where there is recent evidence that corneal elasticity is linked to disease progress 70% of the population. However, it is clear that these measurements are highly susceptible to experimental conditions and cannot be used to map fundamental corneal viscoelastic parameters at high spatial resolution.

Therapeutic interventions, such as UV cross linking, have been monitored with OCE to measure the progression and retardation of collagen degradation.

Current refractive surgery planning uses a population-based average of corneal biomechanics rather than a customized treatment plan, which occasionally produces unpredictable treatment outcomes even with the most conservative selection criteria. The availability of an accurate, personalized corneal biomechanical map of individual cornea from high-resolution OCE may enable a customized treatment plan for each patient, with the biomechanical response adequately predicted for the long term.

Current clinical IOP measurements rely on indirect techniques with limited accuracy because ocular biomechanics cannot be taken into account on a patient-by-patient basis. Available systems used to measure IOP in vivo, such as Goldmann applanation, ORA, and dynamic contour and non-contact tonometry, may be improved by calibration methods that account for corneal mechanical properties. Additionally, it is difficult for conventional (not OCE based) tonometry systems to directly visualize the distribution of local corneal mechanical properties in addition to providing robust estimates of quantitative modulus values. As current clinical gold standards struggle to accurately estimate the influence of corneal mechanical properties on IOP, approaches utilizing available systems may lead to misinformed clinical decision making, a niche where OCE may find great utility.

OCE has also shown utility in lens analysis. With aging, the natural crystalline lens becomes less pliable causing reduced accommodation. This can be directly measurable using OCE methods, as demonstrated using acoustic radiation force (ARF-OCE) to detect age-related stiffness in rabbit lens. It has, however, also been reported that increased IOP affects the shear wave speed in the lens, implying a less understood IOP dependence on lens mechanical moduli.

ARF-OCE has also been demonstrated as a method to assess elasticity within the retina, potentially providing additional information regarding cellular degradation from measurements of retinal and choroidal stiffness, as well as providing further insight into how IOP affects ocular function.



Once reliable and robust measurements of elastic modulus become possible in a noninvasive manner, the micro- and macrostructure of tissue may be used to infer vast amounts of pathophysiological data.



Tuesday, December 12, 2023

DURYSTA INTRACAMERAL IMPLANT

 



Allergan’s DURYSTA biodegradable intracameral implant is the first sustained release device approved by the FDA.




The device is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHTN).

DURYSTA is composed of biodegradable polymers containing 10 mcg of bimatoprost designed to release the drug in a non-pulsatile, steady-state manner over a 90-day period.

Bimatoprost is a prostaglandin analogue which lowers IOP by increasing aqueous humor outflow via both the conventional trabecular route as well as the uveoscleral pathway.

The agent may also increase aqueous humor outflow by decreasing episcleral venous pressure.

FOR SUSTAINED RELEASE MEDICATIONS IN GLAUCOMA FOLLOW THIS LINK: https://ourgsc.blogspot.com/search?q=long+acting

The DURYSTA implant is preloaded within a sterile applicator with a 28-gauge needle tip. Under aseptic conditions, the practitioner inserts the needle into clear cornea, enters the anterior chamber, and then depresses an actuator button to release the implant. Following release of the implant, the needle is removed and the patient is instructed to sit upright for at least one hour so that the implant can rest in the inferior part of the anterior chamber.



Placement of the implant within the anterior chamber angle allows for close proximity to the tissues involved in both of the outflow pathways, where it delivers bimatoprost 24/7 for several months.




A single administration of the bimatoprost implant was found to control IOP in 40% of patients for up to 12 months and in 28% of patients for up to 24 months.

DURYSTA is contraindicated in patients with: active or suspected ocular or periocular infections; corneal endothelial cell dystrophy (e.g., Fuchs’ Dystrophy); prior corneal transplantation or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]); absent or ruptured posterior lens capsule, due to the risk of implant migration into the posterior segment; hypersensitivity to bimatoprost or to any other components of the product.

The commonest adverse effect reported is conjunctival hyperemia, seen in 27% of patients. Other side-effects are foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, increased IOP, corneal endothelial cell loss, blurred vision, iritis, and headache.

Ocular adverse reactions occurring in 1-5% of patients were anterior chamber cell, lacrimation increased, corneal edema, aqueous humor leakage, iris adhesions, ocular discomfort, corneal touch, iris hyperpigmentation, anterior chamber flare, anterior chamber inflammation, and macular edema.

As with other PG analogues, DURYSTA can cause permanent iris pigmentation.

DURYSTA should be used with caution in patients with narrow iridocorneal angles (Shaffer grade < 3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle.

WEBSITE LINKhttps://www.durystahcp.com/index.html

 

 


 


Saturday, December 9, 2023

NANOFIBER-BASED GLAUCOMA DRAINAGE IMPLANT (GDI)

 


Synthetic, nanofiber-based GDIs with partially degradable inner cores have been evaluated in a study to assess the effect of surface topography on implant performance.

It was observed in vitro that nanofiber surfaces supported fibroblast integration and quiescence, even in the presence of pro-fibrotic signals, compared to smooth surfaces.



GDIs with a nanofiber architecture were biocompatible, prevented hypotony, and provided a volumetric aqueous outflow comparable to commercially available GDIs.

The authors were of the opinion that that the physical cues provided by the surface of the nanofiber-based GDIs mimic healthy extracellular matrix structure, reducing fibroblast activation and potentially extending functional GDI lifespan. These tubes were also found to minimize conjunctival fibrosis-related gene expression.

Nanofiber-based stents were found to retain architecture and promote cell integration in vivo. This is in comparison to commercially available implants which were found to activate fibrosis within 1-2 months after implantation, in experimental models.

The nanofiber implants were found to reduce subconjunctival fibrosis. Masson's trichrome staining of tissue surrounding smooth GDIs revealed abundant collagen deposition with a capsular thickness of 610±161μm, whereas the subconjunctival space surrounding the 9mm Nano GDIs was edematous with a capsule thickness of 79±45μm (p = 0.0004). this was also confirmed with quantitative analysis of mean fluorescence intensity (MFI) from αSMA stained IF images which showed that the smooth GDI increased fibroblast activation compared to the Nano GDI.

Comparison of nano-tubes, Baerveldt implant and Xen implant


Experimentally cultured fibroblasts on nanofibers were found to have increased levels of IL-33, MMP-10, IL-6, and COL6A6 transcripts which have been associated with successful, non-fibrotic outcomes. Additionally, nanofibers significantly attenuated the expression of the pro-fibrotic marker MYOCD28, 29 under both stimulated and unstimulated conditions.

https://aiche.onlinelibrary.wiley.com/doi/full/10.1002/btm2.10487





Sunday, December 3, 2023

OCULUS GONIO ready ®


 

The OCULUS GONIO ready ® is a microscope attachment developed by Oculus, that enables the surgeon to perform MIGS procedures easily with both hands.



Currently, the surgeon has to hold the gonio-lens with one hand when performing MIGS procedures.




With this device, the surgeon is free to use both hands and have a bimanual approach when performing glaucoma surgeries.

It is possible to use this attachment with a number of microscopes. The list of compatible microscopes is available at the OCULUS GONIO ready ® website.

https://www.oculussurgical.com/gonioready?utm_campaign=GONIO_ready&utm_source=bmc.glaucoma_today&utm_content=GONIO_ready&utm_medium=sticky_banner.website

The device is for single-use only, overcoming the hassle of sterilization of the gonio-lenses and providing excellent optical quality consistently.

The device is small, yet provides impeccable depth of field and a large field of view (180-degrees), thus, improving the peripheral awareness.




Due to small size of the device, it can be used in pediatric patients also.

The device has a patented Flex System, a flexible “swan neck”, which enables surgeons to allow the lens to float atop the cornea, reducing image distortion and offering better access to corneal incisions for any MIGS device.

This system avoids creating any additional pressure against the patient’s eye, ensuring a more comfortable and relaxing patient experience. Additionally, the Flex System is flexible enough to be moved around during MIGS but is sufficiently resistant to movement so as not to be inadvertently displaced, thus offering consistent, repeatable, and stable lens positioning throughout the procedure.

The device is specifically designed to optimize performance with either a f = 175 mm or f = 200 mm microscope objective lens: 

  • 10011226: GONIO ready® 175, for f = 175 mm
  • 10008420: GONIO ready® 200, for f = 200 mm


 

DEFERIPRONE IN GLAUCOMA MANAGEMENT

  Currently, lowering of intra-ocular pressure (IOP) remains the main therapeutic option for the treatment of glaucoma. However, studies hav...